Skip to main content

Table 1 Characteristics of included ICU patients with SARS-CoV-2 infection according to 60-day outcome

From: Elevated plasma IL-6 and CRP levels are associated with adverse clinical outcomes and death in critically ill SARS-CoV-2 patients: inflammatory response of SARS-CoV-2 patients

Characteristics Total
N = 101
Survivors
N = 82
Non-survivors
N = 19
P value
Men (N, %) 82 (82%) 68 (83%) 14 (74%) 0.35
Age (years) 59 ± 11 57 ± 10 63 ± 11 0.07
SOFA# score 4 [3–7] 4 [3–6] 6 [4–8] 0.005
SAPS II 37 [31–45] 37 [31–44] 41 [33–48] 0.45
Body mass index (kg/m2)
 < 30 63 (63%) 53 (65%) 10 (52%)  
 > 30 38 (38%) 30 (37%) 8 (42%) 0.65
Comorbidity (N, %)
 Hypertension 51 (51%) 44 (54%) 7 (36%) 0.18
 Diabetes mellitus 29 (29%) 23 (28%) 6 (34%) 0.76
 Cardiovascular disease 12 (12%) 10 (12%) 2 (11%) 0.84
 Chronic respiratory disease 18 (18%) 15 (18%) 3 (16%) 0.81
 Chronic kidney disease 14 (14%) 11 (13%) 3 (16%) 0.78
 Cirrhosis 2 (2%) 2 (2%) 0 0.49
 Previous cancer 2 (2%) 2 (2%) 0 0.49
 Haematological malignancy 6 (6%) 5 (6%) 1 (5%) 0.89
Treatment (N, %)
 Glucocorticoids 19 (19%) 16 (19%) 3 (16%) 0.71
 ACE inhibitors 28 (28%) 22 (25%) 6 (31%) 0.67
Organ support therapy at day 0 (N, %)
 Sedative drugs 71 (71%) 55 (67%) 16 (84%) 0.14
 Neuromuscular blockers 57 (57%) 44 (54%) 13 (68%) 0.24
 Mechanical ventilation 83 (83%) 67 (82%) 16 (84%) 0.79
 Prone positioning 53 (53%) 42 (51%) 9 (47%) 0.76
 Haemodialysis 11 (11%) 10 (12%) 1 (5%) 0.38
Norepinephrine
 N (%) 33 (33%) 24 (29%) 9 (47%) 0.13
 Dosage (mg/h) 0 [0–0.22] 0 [0–0.1] 0.1 [0–0.87] 0.07
 Co-infections at day 3 (N, %) 37 (37%) 30 (36%) 7 (37%) 0.98
  1. Data are expressed as N (%) or median (1st IQR–3rd IQR). ACE Angiotensin-Converting Enzyme, NS non-significant